PDCD1 and neoplasm: Since the widely used preclinical GL261 GBM tumor model26 does not recapitulate the poor response to PD1 blockade seen in GBM patients2,16, we generated an αPD1-resistant GBM tumor model (GL261-MGH) (Fig. 1a).